Read more
Key information on Triomab®
Triomab® backgrounder
Trifunctional antibodies (Triomab®) combine the halves of two distinct full-size antibodies, a tumor-specific mouse antibody and a T cell specific rat antibody, in one molecule.
Triomab® antibodies therefore have two different specific binding sites, while traditional antibodies have two identical specific binding sites.
Only the combination of two antibody species (rat and mouse) enabled TRION to overcome production problems encountered by many other types of bispecific antibodies and to establish a pharmaceutical production process. With their GMP approved in-house production facilities, TRION is able to supply the world market.
This format translates into clinical as well as production 
advantages.